COMPANY
Halozyme Therapeutics
FDA-cleared device company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Specialist 2, Quality Systems - Training | San Diego | Oct 22, 2026 | Oct 22, 2026 |
| Director, HCP Marketing & Digital Strategy | Ewing, NJ | Oct 14, 2026 | Oct 15, 2026 |
| Principal Engineer 1, Data Platforms (Microsoft Fabric) | 2 locations (listed on the posting) | Oct 2, 2026 | Oct 9, 2026 |
| Senior Accountant, Accounts Payable & T&E | San Diego | Sep 23, 2026 | Oct 9, 2026 |
| Senior Manager, Cost Accounting | San Diego | Sep 23, 2026 | Oct 9, 2026 |
Raises and deals from press releases
- Deal Incyte deal · amount not disclosed · announced Jul 20, 2026 Company release ↗
Source quote
- Jul 20, 2026 · Company release ↗
“Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology”
- Jul 20, 2026 · Company release ↗
Timeline
- Board tracked Radar started tracking this company’s job board (11 open jobs at last check). source ↗
- Partnership Partnership / licensing announced Oct 6, 2026. Source: company's own press page. source ↗
- Debt Debt: $1.3B (not counted as a raise), announced Sep 17, 2026. Source: SEC filing. source ↗
- Partnership Partnership / licensing announced Jul 20, 2026. Source: company's own press page. source ↗
- Debt Debt: $650M (not counted as a raise), announced Nov 6, 2025. Source: SEC filing. source ↗
- Trial start Phase 3: 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism source ↗
- Trial start Phase 1: Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Lo source ↗
- Trial start Phase 3: A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluro source ↗
- Trial start Phase 1: A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors source ↗
- Trial start 1: A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC source ↗
- Trial start Phase 4: A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) source ↗
- Trial start Phase 2: PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer source ↗
- Trial start Phase 2: Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis source ↗
- Trial start Phase 4: CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) source ↗
- Trial start 1: Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers source ↗
- Trial start Phase 4: Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase source ↗
- Trial start Phase 1/Phase 2: Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer source ↗
- Trial start Phase 1: Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM) source ↗
- Trial start Phase 2: Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus source ↗
- Trial start Phase 2: Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus source ↗
- Trial start Phase 1: Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors source ↗
- Trial start Phase 1: A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone source ↗
- Trial start Phase 2: Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Res source ↗
- Trial start Phase 2: Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus source ↗
- Trial start Phase 1: Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to source ↗
Upcoming milestones
- 2028-03 (ESTIMATED) · Phase 3 · 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism · NCT06689085
Open jobs 11
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Specialist 2, Quality Systems - Training | San Diego | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Director, HCP Marketing & Digital Strategy | Ewing, NJ | Oct 14, 2026 | Oct 15, 2026 | Senior |
| Principal Engineer 1, Data Platforms (Microsoft Fabric) | 2 locations (listed on the posting) | Oct 2, 2026 | Oct 9, 2026 | Senior |
| Senior Accountant, Accounts Payable & T&E | San Diego | Sep 23, 2026 | Oct 9, 2026 | Senior |
| Senior Manager, Cost Accounting | San Diego | Sep 23, 2026 | Oct 9, 2026 | Senior |
| Senior Netsuite Specialist 2, Information Technology Technical Support & Maintenance | 2 locations (listed on the posting) | Sep 23, 2026 | Oct 9, 2026 | Senior |
| Executive Director, Pharmaceutical Manufacturing & Supply Transactions Counsel | San Diego | Sep 23, 2026 | Oct 9, 2026 | Executive |
| Senior Director, Treasury | San Diego | Sep 23, 2026 | Oct 9, 2026 | Senior |
| Senior Director, Accounting | San Diego | Sep 23, 2026 | Oct 9, 2026 | Senior |
| Senior Manager, Revenue & Gross-to-Net | 2 locations (listed on the posting) | Sep 23, 2026 | Oct 9, 2026 | Senior |
| Vice President, Business Development | San Diego | Sep 23, 2026 | Oct 9, 2026 | Executive |
Funding
- Debt: $1.3B (not counted as a raise), announced Sep 17, 2026. Source: SEC filing. source ↗
- Debt: $650M (not counted as a raise), announced Nov 6, 2025. Source: SEC filing. source ↗
- Partnership / licensing announced Oct 6, 2026. Source: company's own press page. source ↗
- Partnership / licensing announced Jul 20, 2026. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 33
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06689085 | 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism | Phase 3 | Recruiting | Mar 7, 2025 | 2028-03 (estimated) |
| NCT00928447 | Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis | Phase 2 | Completed | Jun 23, 2009 | Sep 13, 2009 (actual) |
| NCT00318643 | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer | Phase 1/Phase 2 | Completed | Mar 30, 2006 | Aug 11, 2009 (actual) |
| NCT01839487 | PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | Phase 2 | Completed | May 14, 2013 | May 1, 2018 (actual) |
| NCT02715804 | A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | Phase 3 | Terminated | Mar 14, 2016 | Nov 4, 2019 (actual) |
| NCT02563548 | A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors | Phase 1 | Completed | Oct 22, 2015 | Mar 26, 2019 (actual) |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | Phase 1 | Terminated | Oct 2, 2017 | Nov 11, 2019 (actual) |
| NCT00705536 | Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20 | Phase 1 | Completed | 2007-12 | 2008-02 (actual) |
| NCT01526733 | Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase | Phase 4 | Completed | 2011-12 | 2012-08 (actual) |
| NCT01194245 | Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus | Phase 2 | Completed | 2010-08 | 2011-08 (actual) |
| NCT00774800 | Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus | II | Completed | 2008-10 | 2009-03 (actual) |
| NCT02346370 | A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC | 1 | Terminated | Feb 10, 2015 | Aug 9, 2016 (actual) |
| NCT03662334 | A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) | Phase 4 | Completed | Oct 3, 2013 | Feb 27, 2014 (actual) |
| NCT01453153 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | Phase 1/Phase 2 | Completed | 2011-09 | 2014-02 (actual) |
| NCT00773175 | Subcutaneous Rehydration Compared to Intravenous Rehydration | Phase 4 | Completed | 2008-10 | 2009-11 (actual) |
| NCT01848990 | CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) | Phase 4 | Completed | 2013-03 | 2014-02 (actual) |
| NCT00656370 | Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) | Phase 4 | Completed | 2007-12 | Jan 30, 2008 (actual) |
| NCT00807963 | Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone | Phase 1 | Completed | 2008-12 | Sep 21, 2009 (actual) |
| NCT00803972 | Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20 | Phase 1 | Completed | 2008-11 | Aug 28, 2009 (actual) |
| NCT00883558 | Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus | Phase 2 | Completed | 2009-05 | 2010-02 (actual) |
| NCT01194258 | Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus | Phase 2 | Completed | 2010-08 | 2011-08 (actual) |
| NCT00916357 | Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Completed | 2009-07 | 2009-11 (actual) |
| NCT01275131 | Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM) | Phase 1 | Completed | 2011-01 | 2011-12 (actual) |
| NCT00862849 | Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone | Phase 1 | Completed | 2009-03 | 2009-06 (actual) |
| NCT00979875 | A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone | Phase 1 | Completed | 2009-09 | 2010-02 (actual) |
| NCT01170897 | Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors | Phase 1 | Completed | 2010-07 | 2013-10 (actual) |
| NCT01572012 | Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers | 1 | Completed | 2012-02 | 2013-11 (actual) |
| NCT00834704 | Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors | Phase 1 | Completed | 2009-02 | 2012-06 (actual) |
| NCT00435604 | A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase | Phase 1 | Completed | 2007-02 | Not listed |
| NCT00782587 | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer | Phase 1 | Completed | 2008-10 | 2009-03 (actual) |
| NCT00593281 | INFUSE Morphine Study | Phase 3 | Completed | 2006-01 | 2006-10 (actual) |
| NCT00369187 | Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase | Phase 4 | Completed | 2006-07 | Not listed |
| NCT00311519 | A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects | IIIB | Completed | 2005-11 | Not listed |
Connect
See your connections at Halozyme Therapeutics on LinkedIn (search by name, results not checked)